Results Round-Up: Big Pharma Grapples With China Slowdown
This article was originally published in PharmAsia News
If there was one overall signal to come out of multinationals’ second quarter results, it was that China can no longer be relied upon to be the major driver of growth in emerging markets that it once was, as sales increases are slowing as a result of cost control policies and generic competition. But while several firms’ growth in this market fell into single digits in the quarter, the longer term prospects are still seen as positive given strong underlying fundamentals.
You may also be interested in...
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.